We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ACAD

Price
22.71
Stock movement down
-0.15 (-0.62%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
4.18B
Ent værdi
4.43B
Pris/omsætning
4.50
Pris/bog
7.24
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
32.54
Fremtidig P/E
28.93
PEG
-
EPS-vekst
-28.03%
1 års afkast
57.27%
3 års afkast
13.48%
5 års afkast
-8.83%
10 års afkast
-4.51%
Senest opdateret: 2025-09-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UDBYTTE

ACAD betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E32.54
Pris til OCF20.63
Pris til FCF20.63
Pris til EBITDA46.29
EV i forhold til EBITDA49.00

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning4.50
Pris til egenkapital7.24
EV i forhold til salg4.76

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier168.71M
EPS (TTM)0.77
FCF pr. aktie (TTM)1.22

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)929.24M
Bruttofortjeneste (TTM)851.31M
Driftsindkomst (TTM)112.23M
Nettoindkomst (TTM)128.51M
EPS (TTM)0.77
EPS (1 år frem)0.86

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)91.61%
Driftsmargin (TTM)12.08%
Fortjenstmargin (TTM)13.83%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter155.15M
Nettotilgodehavender98.21M
Omsætningsaktiver i alt788.28M
Goodwill0.00
Immaterielle aktiver105.52M
Ejendomme, anlæg og udstyr48.24M
Sum aktiver976.87M
Kreditor19.08M
Kortfristet/nuværende langsigtet gæld49.37M
Summen af kortfristede forpligtelser343.94M
Sum gæld399.69M
Aktionærernes egenkapital577.18M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)202.73M
Investeringsudgifter (TTM)70.00K
Fri pengestrøm (TTM)202.66M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast22.26%
Afkast af aktiver13.15%
Afkast af investeret kapital21.92%
Kontant afkast af investeret kapital34.58%

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning24.76
Daglig høj25.07
Daglig lav24.63
Daglig volumen999K
Højeste gennem alle tider57.00
1 års analytiker estimat29.95
Beta0.70
EPS (TTM)0.77
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation11 Nov 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACADS&P500
Nuværende prisfald fra top notering-56.52%-1.46%
Højeste prisfald-96.29%-56.47%
Højeste efterår dato12 Nov 20109 Mar 2009
Gennemsnitlig fald fra toppen-49.84%-10.99%
Gennemsnitlig tid til nyt højdepunkt57 days12 days
Maks. tid til nyt højdepunkt1820 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
ACAD (ACADIA Pharmaceuticals Inc) company logo
Markedsværdi
4.18B
Markedsværdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Personale
653
Investor relationer
-
SEC-indsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...